Background: Excessive inflammatory response, neuronal loss, and demyelination mediate the pathogenesis of spinal cord injury (SCI). VX-765, a highly selective caspase-1 inhibitor, is recently revealed to control pyroptosis in some disease models. However, the effects and underlying mechanisms of VX-765 in SCI remains unclear. Methods: Functional recovery was assessed using Basso Mouse Scale (BMS) and BMS subscore. Proinflammatory cytokines levels was evaluated by western blot or enzyme-linked immunosorbent assay. The number of neutrophils was assessed by flow cytometry. Neuronal loss was evaluated by immunochemistry staining of NeuN. Demyelination was evaluated using immunofluorescence staining of myelin basic protein. Results: Here we report that VX-765 led to a significant recovery of hindlimb locomotor function after SCI in mice. Moreover, VX-765 prevented caspase-1 activation, inhibited pyroptosis of neuron and oligodendrocyte, reduced proinflammatory cytokines levels and loss of neuron and myelin, and declines the number of neutrophils in mice. Furthermore, VX-765 suppressed caspase-1 activation, decreased proinflammatory cytokine levels, diminished pyroptosis and promoted the survival of neurons in oxygen-glucose deprivation oligodendrocytes.Conclusions: Together, our data indicate that VX-765 provide a novel potential therapy strategy to improve recovery after SCI.